Meridee McArthur
Psychiatric/Mental Health · Calhoun, GANPI 1447629837
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 481 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 481 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Neurocrine Biosciences, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$949
- Teva Pharmaceuticals USA, Inc.$739
- Supernus Pharmaceuticals, Inc.$436
- Otsuka America Pharmaceutical, Inc.$408
- plus $2K from 19 others
What the payments were for
- Food & beverage$7,68699%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 207 | $1,719 |
| Neurocrine Biosciences, Inc. | 39 | $1,017 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 54 | $949 |
| Teva Pharmaceuticals USA, Inc. | 31 | $739 |
| Supernus Pharmaceuticals, Inc. | 16 | $436 |
| Otsuka America Pharmaceutical, Inc. | 15 | $408 |
| Johnson & Johnson | 16 | $355 |
| Vanda Pharmaceuticals Inc. | 12 | $320 |
| Alkermes, Inc. | 14 | $299 |
| Lundbeck LLC | 14 | $277 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $274 |
| Noven Therapeutics, LLC | 14 | $246 |
| Axsome Therapeutics, Inc. | 7 | $183 |
| Almatica Pharma LLC | 8 | $132 |
| E.r. Squibb & Sons, L.L.C. | 5 | $100 |
| Eisai Inc. | 3 | $48 |
| Idorsia Pharmaceuticals US Inc | 2 | $46 |
| Tris Pharma Inc | 2 | $44 |
| Bausch Health US, LLC | 2 | $43 |
| Merck | 2 | $26 |
| Noven Pharmaceuticals, Inc. | 1 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Currax Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,745 in reported general payments places this provider in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 15 | $207,686 |
| IngrezzaValbenazine Tosylate | 13 | $109,345 |
| Abilify MaintenaAripiprazole | 22 | $67,278 |
| VraylarCariprazine Hcl | 33 | $51,882 |
| CaplytaLumateperone Tosylate | 26 | $47,580 |
| FanaptIloperidone | 14 | $28,539 |
| BelsomraSuvorexant | 17 | $11,228 |
| Lurasidone Hcl | 40 | $8,879 |
| Oxcarbazepine | 71 | $4,386 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 55 | $2,981 |
| Paliperidone ErPaliperidone | 11 | $2,779 |
| Lamotrigine | 130 | $2,677 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 19 | $2,514 |
| Quetiapine Fumarate | 148 | $2,440 |
| Fluphenazine Hcl | 25 | $2,261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $739 | $207,68615 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,017 | $109,34513 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $408 | $67,27822 claims |
| AbbVieVraylar | $1,719 | $51,88233 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $949 | $47,58026 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $320 | $28,53914 claims |
| MerckBelsomra | $26 | $11,22817 claims |
| Almatica Pharma LLCSertraline Hcl | $132 | $33247 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Other psychiatric/mental health in Calhoun
- Jessica FreemanCalhoun$7K
- Phyillis Kennedy-HowellBarney$673K
- Jessica OliverThomasville$233K
- Sherri KrollBrunswick$155K
- Taylor LeblancAlbany$48K
- Greta HeckmannDalton$28K
- Matthew DowdyWoodstock$25K
- Natasha GilesLoganville$21K
- Darrick SealeyWarner Robins$17K
- Olufunke AdewunmiSmyrna$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.